Proud to share our latest publication in JCO Precision Oncology @JCOPO_ASCO@JCO_ASCO@RamSubraMD@BPonvilawan
In the largest study to date evaluating transcriptomic immune biomarkers in advanced NSCLC treated with immunotherapy, we found that:
• Immune-hot tumor microenvironments and high tertiary lymphoid structure (TLS) signatures were strongly associated with improved immunotherapy outcomes in lung adenocarcinoma
• These biomarkers outperformed traditional markers like PD-L1 in predicting benefit
• Dynamic immune trafficking and activation may be key drivers of response to checkpoint inhibitors
Excited about the potential for RNA-based immune profiling to refine precision immunotherapy in lung cancer.
#LungCancer #NSCLC #Immunotherapy #PrecisionOncology #ThoracicOncology #CancerResearch
https://t.co/sZtZXOeEi8
#ASCO25 Day 2: so proud of our two stellar residents, soon to be fellows! @Meddoc77 (Himil Mahadevia) and Parth Sharma. Congrats on the posters, can’t wait to see what your futures hold! @SLCI_KC@saintlukeskc
🤩Honored to be a co-author on this important work led by our incredible attending Dr. Arya @royaryam, spotlighting the academic productivity of IMG fellows. Grateful for the opportunity to contribute!🙌
📅 Oral Presentation: 6/2/2025 | 9:45–9:51 AM
🔗 https://t.co/6uQXhbgl8K
#ASCO2025 #IMG #MedTwitter #HemOnc #Oncology #Research
🚨Save the date🚨
@ASCO#IMG Community of Practice Meeting at #ASCO25
⏰May 30st, 4-6 PM CST
📌Room S103, McCormick Place
Join us to discuss barriers & opportunities for IMGs
ASCO IMG CoP👉https://t.co/ke4h9obYok
@ASCOPost#IMGoncCoP#MedEd#MedTwitter
We encourage you to check out our article on tips for finding a HemeOnc job in the U.S. while on a J1 visa. It offers practical advice from individuals who have navigated the same process! @ASCO#ASCOConnections@RohitBanwar
🎤 Excited to present at the #NCCN2025 Conference! @NCCN
📊 Racial Disparities in NSCLC Survival Outcomes: A Systematic Review & Meta-Analysis
✅ Asian/API patients had significantly better OS vs. White patients
❌ No significant differences in OS for Black or Hispanic patients
🔍 Our findings highlight genomic drivers & evolving treatment access. Let’s advance equity in lung cancer care.
@OncoAlert@NCCNnews
🧠 #Oncology #LungCancer #NSCLC #HealthEquity #CancerDisparities #CancerResearch #MedTwitter
Our paper recently published in @JAMANetworkOpen Doublet IO might be more beneficial in patients with pd-l1 negative squamous cell lung cancer
https://t.co/DwaSvjbf6x
Excited to celebrate the outstanding fellowship match results of our UMKC Internal Medicine residents! We’re proud of your achievements and look forward to your continued success in the next chapter of your careers. #UMKCIM#FellowshipMatch2024